Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1851 results
March 2020
-
Story From Our Labs
Advancing medicine through collaboration
In Wendi Yajnik’s quest to find new technologies that could transform medicine, relationships are priority No. 1.
-
Story Discovery
Clinical trial comes together in weeks to address coronavirus
Researchers race to put hydroxychloroquine to the test in a large study.
-
Press release
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million. The PAMAfrica consortium brings… -
Ad hoc release
Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.
Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long…
February 2020
-
Ad hoc release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 23rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5%1 yield and approximately 54% payout of free cash flow Shareholders confirm Dr.… -
Ad hoc release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration à l’Assemblée générale annuelle
Les actionnaires approuvent la 23e augmentation consécutive du dividende qui passe à CHF 2.95 (+4%) par action pour l’année 2019, soit un rendement de 3,5%1 et une distribution du free cash-flow… -
Story People and Culture
Parental Leave at Novartis: Alfred’s story
At Novartis, we celebrate life and recognize moments that matter. Alfred Ambatlle shares his experience of parental leave and becoming a father of twins.
-
Press release
Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis
LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust Novartis is responsible for completing Phase I clinical trials and has committed to… -
Story Discovery
Shaping the future of sickle cell disease
Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.
-
Press release
Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)
Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as… -
Story Access to Healthcare
Collaboration is strengthening care for chronic illness in Ethiopia
Working with a nonprofit, Novartis is helping train healthcare workers to diagnose and treat chronic ailments such as diabetes.
-
Press release
Novartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide
Beovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on three-month dosing intervals immediately after the loading…